| Autor: |
Woodburn SC; Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York 14853, United States., Levitt CM; Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York 14853, United States., Koester AM; Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York 14853, United States., Kwan AC; Meinig School of Biomedical Engineering, Cornell University, Ithaca, New York 14853, United States.; Department of Psychiatry, Weill Cornell Medicine, New York, New York 10065, United States. |
| Jazyk: |
angličtina |
| Zdroj: |
ACS chemical neuroscience [ACS Chem Neurosci] 2024 Aug 21; Vol. 15 (16), pp. 3034-3043. Date of Electronic Publication: 2024 Aug 01. |
| DOI: |
10.1021/acschemneuro.4c00279 |
| Abstrakt: |
A variety of classic psychedelics and MDMA have been shown to enhance fear extinction in rodent models. This has translational significance because a standard treatment for post-traumatic stress disorder (PTSD) is prolonged exposure therapy. However, few studies have investigated psilocybin's potential effect on fear learning paradigms. More specifically, the extents to which dose, timing of administration, and serotonin receptors may influence psilocybin's effect on fear extinction are not understood. In this study, we used a delay fear conditioning paradigm to determine the effects of psilocybin on fear extinction, extinction retention, and fear renewal in male and female mice. Psilocybin robustly enhances fear extinction when given acutely prior to testing for all doses tested. Psilocybin also exerts long-term effects to elevate extinction retention and suppress fear renewal in a novel context, although these changes were sensitive to dose. Analysis of sex differences showed that females may respond to a narrower range of doses than males. Administration of psilocybin prior to fear learning or immediately after extinction yielded no change in behavior, indicating that concurrent extinction experience is necessary for the drug's effects. Cotreatment with a 5-HT 2A receptor antagonist blocked psilocybin's effects for extinction, extinction retention, and fear renewal, whereas 5-HT 1A receptor antagonism attenuated only the effect on fear renewal. Collectively, these results highlight dose, context, and serotonin receptors as crucial factors in psilocybin's ability to facilitate fear extinction. The study provides preclinical evidence to support investigating psilocybin as a pharmacological adjunct for extinction-based therapy for PTSD. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
